

Actinium Pharmaceuticals, Inc.  
Form 8-K  
August 03, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): July 29, 2015

**ACTINIUM PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>000-52446</b> (Commission File Number)	<b>74-2963609</b> (IRS Employer Identification No.)
--	--	---

<b>757 Third Avenue, 21<sup>st</sup> Floor</b> <b>New York, NY</b> (Address of principal executive offices)	<b>10017</b> (Zip Code)
---	----------------------------

Registrant's telephone number, including area code: **(646) 459-4201**

Edgar Filing: Actinium Pharmaceuticals, Inc. - Form 8-K

**546 Fifth Avenue, 14<sup>th</sup> Floor, NY, NY 10036**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

**Item 2.02. Results of Operations and Financial Condition.**

In a letter to shareholders, dated July 29, 2015, Actinium Pharmaceuticals, Inc. (the "Company") reported that its pro forma cash position at June 30, 2015 was approximately \$27 million. A copy of the shareholder letter is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 2.02 by reference.

**Item 7.01. Regulation FD Disclosure.**

A copy of a shareholder letter mailed to Company shareholders on July 29, 2015 is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

The response to Item 2.02 is incorporated herein by reference to this Item 7.01.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Letter to Shareholders, dated July 29, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ACTINIUM PHARMACEUTICALS, INC.**

Dated: August 3, 2015 By: */s/ Kaushik J. Dave*

Name: Kaushik J. Dave

Title: President and Chief Executive Officer